Human Genome Epidemiology Literature Finder
Records 1 - 27 (of 27 Records) |
Query Trace: Diarrhea and MET[original query] |
---|
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England journal of medicine 2009 Sep 361 (10): 947-57. Mok Tony S, Wu Yi-Long, Thongprasert Sumitra, Yang Chih-Hsin, Chu Da-Tong, Saijo Nagahiro, Sunpaweravong Patrapim, Han Baohui, Margono Benjamin, Ichinose Yukito, Nishiwaki Yutaka, Ohe Yuichiro, Yang Jin-Ji, Chewaskulyong Busyamas, Jiang Haiyi, Duffield Emma L, Watkins Claire L, Armour Alison A, Fukuoka Masahi |
Association of clinical and genetical features in FMF with focus on MEFV strip assay sensitivity in 452 children from western Anatolia, Turkey. Clinical rheumatology 2012 Mar 31 (3): 493-501. Ozturk Can, Halicioglu Oya, Coker I?il, Gulez Nesrin, Sutçuoglu Sumer, Karaca Neslihan, Aksu Guzide, Kutukculer Nec |
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Apr 31 (11): 1405-14. Argiris Athanassios, Ghebremichael Musie, Gilbert Jill, Lee Ju-Whei, Sachidanandam Kamakshi, Kolesar Jill M, Burtness Barbara, Forastiere Arlene |
Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Expert review of clinical pharmacology 2015 Nov 1-11. Krajewska Jolanta, Olczyk Tomasz, Jarzab Barba |
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget 2017 Aug 8 (34): 57528-57536. Kim Lucia, Saieg Mauro, Di Maio Massimo, Gallo Ciro, Butts Charles, Ciardiello Fortunato, Feld Ronald, Cheng Dengxiao, Gebbia Vittorio, Burgio Marco Angelo, Alam Yasmin, Signoriello Simona, Rossi Antonio, Leighl Natasha, Maione Paolo, Morabito Alessandro, Liu Geoffrey, Tsao Ming-Sound, Perrone Francesco, Gridelli Cesa |
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. Cancer chemotherapy and pharmacology 2017 Mar . Wakelee Heather A, Gettinger Scott, Engelman Jeffrey, Jänne Pasi A, West Howard, Subramaniam Deepa S, Leach Joseph, Wax Michael, Yaron Yifah, Miles Dale R, Lara Primo |
HTR3A and HTR3E gene polymorphisms and diarrhea predominant irritable bowel syndrome risk: evidence from a meta-analysis. Oncotarget 2017 (59): 100459-100468. Guan Tangming, Li Ting, Cai Weiming, Huang Dong, Ouyang Peipei, Wang Yan, Chen Huayan, Wu Kefeng, Ma Xiao |
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget 2017 Sep 8 (41): 69651-69662. Leighl Natasha B, Tsao Ming-Sound, Liu Geoffrey, Tu Dongsheng, Ho Cheryl, Shepherd Frances A, Murray Nevin, Goffin John R, Nicholas Garth, Sakashita Shingo, Chen Zhuo, Kim Lucia, Powers Jean, Seymour Lesley, Goss Glenwood, Bradbury Penelope |
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Medical oncology (Northwood, London, England) 2018 May 35 (7): 101. Papaxoinis George, Kotoula Vassiliki, Giannoulatou Eleni, Koliou Georgia-Angeliki, Karavasilis Vasilios, Lakis Sotirios, Koureas Andreas, Bobos Mattheos, Chalaralambous Elpida, Daskalaki Emily, Chatzopoulos Kyriakos, Tsironis George, Pazarli Elisavet, Chrisafi Sofia, Samantas Epaminontas, Kaklamanos Ioannis G, Varthalitis Ioannis, Konstantara Athina, Syrigos Konstantinos N, Pentheroudakis George, Pectasides Dimitrios, Fountzilas Geor |
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 5 13 (9): 1363-1372. Gettinger Scott, Hellmann Matthew D, Chow Laura Q M, Borghaei Hossein, Antonia Scott, Brahmer Julie R, Goldman Jonathan W, Gerber David E, Juergens Rosalyn A, Shepherd Frances A, Laurie Scott A, Young Tina C, Li Xuemei, Geese William J, Rizvi Naiy |
First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 4 13 (7): 968-977. Ma Yuxiang, Zheng Xin, Zhao Hongyun, Fang Wenfeng, Zhang Yang, Ge Jieying, Wang Lu, Wang Weicong, Jiang Ji, Chuai Shaokun, Zhang Zhou, Xu Wanhong, Xu Xiao, Hu Pei, Zhang |
G protein beta 3(GN?3) C825T polymorphism and irritable bowel syndrome susceptibility: an updated meta-analysis based on eleven case-control studies. Oncotarget 2018 2 9 (2): 2770-2781. Jiang Dongbo, Huang Dong, Cai Weiming, Li Ting, Wang Yan, Chen Huayan, Guan Tangming, Ma Xiao |
Clinical Features, Molecular Genetics, and Long-Term Outcome in Congenital Chloride Diarrhea: A Nationwide Study in Japan. The Journal of pediatrics 2019 9 214 151-157.e6. Konishi Ken-Ichiro, Mizuochi Tatsuki, Yanagi Tadahiro, Watanabe Yoriko, Ohkubo Kazuhiro, Ohga Shouichi, Maruyama Hidehiko, Takeuchi Ichiro, Sekine Yuji, Masuda Kei, Kikuchi Nobuyuki, Yotsumoto Yuka, Ohtsuka Yasufumi, Tanaka Hidenori, Kudo Takahiro, Noguchi Atsuko, Fuwa Kazumasa, Mushiake Sotaro, Ida Shinobu, Fujishiro Jun, Yamashita Yushiro, Taguchi Tomoaki, Yamamoto K |
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. Therapeutic advances in medical oncology 2019 6 11 1758835919846421. Bruera Gemma, Massacese Silvia, Pepe Francesco, Malapelle Umberto, Dal Mas Antonella, Ciacco Eugenio, Calvisi Giuseppe, Troncone Giancarlo, Simmaco Maurizio, Ricevuto Enri |
Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer. Clinical lung cancer 2019 2 20 (3): e317-e328. Nokihara Hiroshi, Nishio Makoto, Yamamoto Noboru, Fujiwara Yutaka, Horinouchi Hidehito, Kanda Shintaro, Horiike Atsushi, Ohyanagi Fumiyoshi, Yanagitani Noriko, Nguyen Linh, Yaron Yifah, Borgman Anne, Tamura Tomohi |
Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial. Lung cancer (Amsterdam, Netherlands) 2020 8 147 209-213. Fan Yun, Chen Jianhua, Zhou Chengzhi, Wang Huijuan, Shu Yongqian, Zhang Jacky, Hua Hairui, Huang Dennis Chin-Lun, Zhou Caic |
Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcoholism, clinical and experimental research 2020 Aug . Anton Raymond F, Voronin Konstantin E, Book Sarah W, Latham Patricia K, Randall Patrick K, Glen Willam Bailey, Hoffman Michaela, Schacht Joseph |
A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. Oncotarget 2020 4 11 (14): 1235-1243. Taylor Matthew H, Alva Ajjai S, Larson Timothy, Szpakowski Sebastian, Purkaystha Das, Amin Alpesh, Karpiak Linda, Piha-Paul Sarina |
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Jan . Dhani Neesha C, Hirte Hal W, Wang Lisa, Burnier Julia V, Jain Angela, Butler Marcus O, Welch Stephen, Fleming Gini F, Hurteau Jean, Matsuo Koji, Matei Daniela, Jimenez Waldo, Johnston Carolyn, Cristea Mihaela, Tonkin Katia, Ghatage Prafull, Lheureux Stephanie, Mehta Anjali, Quintos Judy, Tan Qian, Kamel-Reid Suzanne, Ludkovski Olga, Tsao Ming-Sound, Wright John J, Oza Amit |
A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632. Lung cancer (Amsterdam, Netherlands) 2021 9 161 49-54. Noro Rintaro, Igawa Satoshi, Bessho Akihiro, Hirose Takashi, Shimokawa Tsuneo, Nakashima Masanao, Minato Koichi, Seki Nobuhiko, Tokito Takaaki, Harada Toshiyuki, Sasada Shinji, Miyamoto Shingo, Tanaka Yosuke, Furuya Naoki, Kaburagi Takayuki, Hayashi Hideki, Iihara Hirotoshi, Okamoto Hiroaki, Kubota Kao |
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA oncology 2021 Aug . Martinelli Erika, Martini Giulia, Famiglietti Vincenzo, Troiani Teresa, Napolitano Stefania, Pietrantonio Filippo, Ciardiello Davide, Terminiello Marinella, Borrelli Carola, Vitiello Pietro Paolo, De Braud Filippo, Morano Federica, Avallone Antonio, Normanno Nicola, Nappi Anna, Maiello Evaristo, Latiano Tiziana, Falcone Alfredo, Cremolini Chiara, Rossini Daniele, Santabarbara Giuseppe, Pinto Carmine, Santini Daniele, Cardone Claudia, Zanaletti Nicoletta, Di Liello Alessandra, Renato Daniela, Esposito Lucia, Marrone Francesca, Ciardiello Fortuna |
Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. Frontiers in molecular biosciences 2021 5 8 639892. Yang Xue, Xia Yang, Xu Liyan, Liang Li, Zhuo Minglei, Wu Meina, An Tongtong, Wang Ziping, Wang Yuyan, Li Jianjie, Zhong Jia, Chen Hanxiao, Jia Bo, Wang Jingjing, Zhao J |
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. Drug safety 2021 12 45 (1): 45-64. Nadal Ernest, Horinouchi Hidehito, Shih Jin-Yuan, Nakagawa Kazuhiko, Reck Martin, Garon Edward B, Wei Yu-Feng, Kollmeier Jens, Frimodt-Moller Bente, Barrett Emily, Lipkovich Olga, Visseren-Grul Carla, Novello Silv |
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2). BMC medicine 2022 8 20 (1): 277. Yang Guangjian, Xu Haiyan, Yang Yaning, Zhang Shuyang, Xu Fei, Hao Xuezhi, Li Junling, Xing Puyuan, Hu Xingsheng, Liu Yutao, Wang Lin, Lin Lin, Wang Zhijie, Duan Jianchun, Wang Jie, Wang Y |
Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Jun OF1-OF10. Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 5 . Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
[Irritable bowel syndrome phenotypes: leading factors of genetics and epigenetics, mechanisms of formation]. Terapevticheskii arkhiv 2023 5 95 (2): 164-172. O V Gaus, M A Livz |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: